For the Inventor, By the Inventor

Enter inventor name

East Windsor, NJ, United States of America

Zili Xiao

USPTO Granted Patents = 22 (Patent Applications = 7)

EPO Patents = 10 (Patent Applications = 10)

Average Co-Inventor Count = 5.9

ph-index = 3

Forward Citations = 29(Granted Patents)

Location History:

West Windsor, NJ (US) (2007 - 2010)
East Windsor, NJ (US) (2016 - 2024)

Company Filing History:

22 out of 3,681

Bristol-myers Squibb Compnay

Years Active: 2007-2025

Loading Chart...

Loading Chart...

22 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12473290 - Imidazopyridazine compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses (2025-11-18),

2. 12365667 - Sulfone pyridine alkyl amide-substituted heteroaryl compounds (2025-07-22),

3. 12110290 - Triazolopyridinyl compounds as kinase inhibitors (2024-10-08),

4. 11866414 - Substituted heterocyclic compounds (2024-01-09),

5. 11787779 - Sulfone pyridine alkyl amide-substituted heteroaryl compounds (2023-10-17),

6. 11767322 - Triazolopyridinyl compounds as kinase inhibitors (2023-09-26),

7. 11701373 - Substituted bicyclic compounds (2023-07-18),

8. 11597721 - Heterocyclic compounds comprising pyridine useful as modulators of IL-12, IL-23 and/or IFNα responses (2023-03-07),

9. 11058696 - Substituted bicyclic compounds (2021-07-13),

10. 11021462 - Sulfone pyridine alkyl amide-substituted heteroaryl compounds (2021-06-01),

11. 10709719 - Substituted bicyclic compounds (2020-07-14),

12. 10633339 - Tricyclic sulfone compound as a ROR gamma modulator (2020-04-28),

13. 10435369 - Tricyclic sulfones as ROR gamma modulators (2019-10-08),

14. 10294256 - Phosphine oxide alkyl amide substituted heteroaryl compounds as modulators of IL-12, IL-23 and/or IFN alpha responses (2019-05-21),

15. 10166249 - Substituted bicyclic compounds (2019-01-01),

Title: Zili Xiao: A Pioneer in Kinase Inhibitor Innovation

Introduction

Zili Xiao, based in East Windsor, NJ, is a distinguished inventor with a remarkable portfolio consisting of 20 patents. His innovative work primarily focuses on the development of compounds that target key biological mechanisms, particularly in the field of kinase inhibitors.

Latest Patents

Among Zili Xiao's latest patents, one notable invention is centered around triazolopyridinyl compounds as kinase inhibitors. These compounds, described as having formula (I) and various enantiomers, diastereomers, and stereoisomers, demonstrate potential as kinase modulators including RIPK1 modulation. Another significant patent highlights substituted heterocyclic compounds, which are useful in modulating IL-12, IL-23, and/or IFNα. These compounds target Tyk-2 to inhibit signal transduction and may hold promise for treating neurodegenerative diseases and disorders.

Career Highlights

Zili Xiao's career has been significantly enriched by his role at Bristol-Myers Squibb Company, where he has contributed to groundbreaking research and development initiatives. His work is characterized by a commitment to translating complex scientific concepts into practical applications that can enhance therapeutic options.

Collaborations

Throughout his career, Zili has collaborated with accomplished professionals such as Michael G. Yang and T.G. Murali Dhar. These partnerships not only foster creativity but also amplify the impact of their collective research efforts in the pharmaceutical industry.

Conclusion

Zili Xiao's innovative contributions, particularly in kinase inhibition and therapeutic development for neurodegenerative diseases, showcase his importance in the field of pharmaceutical sciences. His patents serve as a testament to his expertise and commitment to advancing medical treatment and understanding of complex biological systems.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com

Loading…